Pfizer-Pharmawert total unterbewertet! 50% möglich! (Seite 245)
eröffnet am 15.05.06 13:00:41 von
neuester Beitrag 16.05.24 11:38:32 von
neuester Beitrag 16.05.24 11:38:32 von
Beiträge: 2.484
ID: 1.060.098
ID: 1.060.098
Aufrufe heute: 5
Gesamt: 332.612
Gesamt: 332.612
Aktive User: 0
ISIN: US7170811035 · WKN: 852009 · Symbol: PFE
28,92
USD
+0,35 %
+0,10 USD
Letzter Kurs 02:04:00 NYSE
Neuigkeiten
16.05.24 · Felix Haupt Anzeige |
13.05.24 · BNP Paribas Anzeige |
13.05.24 · dpa-AFX |
07.05.24 · inv3st.de Anzeige |
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
0,5100 | +134,48 | |
0,7000 | +75,00 | |
1,8150 | +34,44 | |
0,6035 | +28,41 | |
15,348 | +19,53 |
Wertpapier | Kurs | Perf. % |
---|---|---|
12,330 | -10,33 | |
1,7000 | -10,53 | |
0,8209 | -22,56 | |
0,7800 | -29,73 | |
5,0100 | -90,93 |
Beitrag zu dieser Diskussion schreiben
Antwort auf Beitrag Nr.: 25.464.064 von Hoellbache am 16.11.06 18:07:29Entscheidung morgen!
Nochaml zu 0,27€ nachgelegt....
Short mit:
WKN CB5517
Produktart Unlimited Turbo Zertifikate
Basiswert Pfizer Inc
Typ Bear
[URL]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1794330[/URL]
[URLChart öffnen]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1794330[/URL]
Ansonsten werde ich endgültig auf einen Knock out (long) umsteigen!
Nochaml zu 0,27€ nachgelegt....
Short mit:
WKN CB5517
Produktart Unlimited Turbo Zertifikate
Basiswert Pfizer Inc
Typ Bear
[URL]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1794330[/URL]
[URLChart öffnen]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1794330[/URL]
Ansonsten werde ich endgültig auf einen Knock out (long) umsteigen!
Antwort auf Beitrag Nr.: 25.464.041 von Hoellbache am 16.11.06 18:05:41Den hab ich ir bei 0,29€ gegönnt...
CB5517
CB5517
Jetzt Pfizer shorten? Oder war das die "Three - White - Soldiers" Formation
Ich probiers mal!
[URL]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1794030[/URL]
[URLChart öffnen]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1794030[/URL]
Ich probiers mal!
[URL]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1794030[/URL]
[URLChart öffnen]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1794030[/URL]
Innere Trendlinie durchbrochen:
Nächstes KZ 27$, dort werd ich dann short gehen...
[URL]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1792324[/URL]
[URLChart öffnen]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1792324[/URL]
Nächstes KZ 27$, dort werd ich dann short gehen...
[URL]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1792324[/URL]
[URLChart öffnen]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1792324[/URL]
15.11.2006 18:40
PFIZER INC: Research Update - Pfizer's HCP
Results of New Combined Analysis Concludes Patients at Risk for Glaucoma Will
Benefit From Risk Assessment Tool
- New data confirm a five-year risk assessment tool will help
ophthalmologists better predict which patients have an increased risk
of developing glaucoma
- Analysis finds that patients with elevated intraocular pressure (IOP)
- along with other predictive risk factors, such older age (40+) -
are at highest risk of progressing to primary open-angle glaucoma
(POAG)
- Investigator: 'It is critical to continue to evaluate and refine
innovative, predictive models in ophthalmic medicine in order to
provide the best treatment possible for patients.'
LAS VEGAS, Nov. 15 -- A combined analysis of two landmark clinical
glaucoma trials -- the Ocular Hypertension Treatment Study (OHTS) and the
European Glaucoma Prevention Study (EGPS) -- confirms the benefit of a five-
year risk assessment model to help ophthalmologists better predict which
patients have an increased risk of developing glaucoma. Glaucoma is the
second leading cause of blindness in the world, affecting approximately 70
million people, and can lead to blindness if left untreated. These new data
were presented this week at the annual American Academy of Ophthalmology
meeting.
The analysis showed that patients with elevated intraocular pressure (IOP)
-- along with other predictive risk factors, such as older age (40+) -- are at
highest risk of progressing to primary open-angle glaucoma (POAG). The
results are similar to the 2005 risk-assessment model reported by Dr. Robert
N. Weinreb and Dr. Felipe A. Medeiros based on findings from the 2002 Ocular
Hypertension Treatment Study (OHTS), a five-year National Eye Institute-
sponsored trial that found early intervention with IOP-lowering medications
could prevent glaucoma in at-risk patients.
"It is critical to continue to evaluate and refine innovative, predictive
models in ophthalmic medicine in order to provide the best treatment possible
for patients," said Dr. Michael Kass. "We hope this tool will become as
universally adapted as predictive models used in other therapeutic areas, such
as the Framingham Study, which provided a basis for accurate cardiac risk
assessment."
"For some time we have known that if we could identify those patients most
likely to progress to glaucoma, earlier intervention with effective treatments
could help reduce the risk of vision impairment," said Dr. Robert N. Weinreb,
director of the Hamilton Glaucoma Center and Distinguished Professor of
Ophthalmology at the University of California, San Diego, USA. "This new
analysis provides a larger-scale validation of breakthrough findings of the
OHTS group and reinforces to clinicians how the tool can be useful in
assessing which patients are most at risk."
The OHTS prediction model was tested on patients in the EGPS placebo group
and the two study samples from the control (non-treated) arms were pooled to
increase precision and generalizability of a five-year predictive model for
developing POAG. The OHTS observation group contained 819 patients with a
median follow up of every six months for 6.6 years. The EGPS placebo group
contained 500 patients with a median follow up of every six months for 4.8
years.
"We know that awareness of these predictors, particularly elevated
intraocular pressure, and central corneal thickness, is critical in treating
and potentially preventing damage to the optic nerve caused by glaucoma
progression," said Professor Stefano Miglior, director of the Department of
Ophthalmology, Policlinico di Monza, University of Milan Bicocca, Italy, and
Chairman of EGPS. "The large-scale validation, which includes a European
patient population for the first time, reinforces the consensus about the
importance of informed dialogue between physicians and patients on how often
eye examinations are needed and when it might be appropriate to initiate
treatment."
The research was supported by grants from Pfizer Inc, (Nachrichten/Aktienkurs) the National Eye
Institute and the National Center for Minority Health and Health Disparities,
National Institutes of Health, the European Commission and Research to Prevent
Blindness and Merck Research Laboratories.
Pfizer's current product line includes the most prescribed treatment to
lower elevated eye pressure in patients with ocular hypertension (abnormally
high eye pressure) or open-angle glaucoma. In collaboration with (OSI)
Eyetech, the division also includes a treatment for neovascular age-related
macular degeneration.
SOURCE Pfizer Inc
-0- 11/15/2006
/CONTACT: Judy Brooks of Pfizer Inc, +1-212-573-7897/
/Photo: A free corporate logo to accompany this story is available
immediately via Wieck Photo Database to any media with telephoto receiver
or electronic darkroom, PC or Macintosh, that can accept overhead
transmissions. To retrieve a logo, please call 972-392-0888./
/Web site: http://www.pfizer.com /
(PFE)
PFIZER INC: Research Update - Pfizer's HCP
Results of New Combined Analysis Concludes Patients at Risk for Glaucoma Will
Benefit From Risk Assessment Tool
- New data confirm a five-year risk assessment tool will help
ophthalmologists better predict which patients have an increased risk
of developing glaucoma
- Analysis finds that patients with elevated intraocular pressure (IOP)
- along with other predictive risk factors, such older age (40+) -
are at highest risk of progressing to primary open-angle glaucoma
(POAG)
- Investigator: 'It is critical to continue to evaluate and refine
innovative, predictive models in ophthalmic medicine in order to
provide the best treatment possible for patients.'
LAS VEGAS, Nov. 15 -- A combined analysis of two landmark clinical
glaucoma trials -- the Ocular Hypertension Treatment Study (OHTS) and the
European Glaucoma Prevention Study (EGPS) -- confirms the benefit of a five-
year risk assessment model to help ophthalmologists better predict which
patients have an increased risk of developing glaucoma. Glaucoma is the
second leading cause of blindness in the world, affecting approximately 70
million people, and can lead to blindness if left untreated. These new data
were presented this week at the annual American Academy of Ophthalmology
meeting.
The analysis showed that patients with elevated intraocular pressure (IOP)
-- along with other predictive risk factors, such as older age (40+) -- are at
highest risk of progressing to primary open-angle glaucoma (POAG). The
results are similar to the 2005 risk-assessment model reported by Dr. Robert
N. Weinreb and Dr. Felipe A. Medeiros based on findings from the 2002 Ocular
Hypertension Treatment Study (OHTS), a five-year National Eye Institute-
sponsored trial that found early intervention with IOP-lowering medications
could prevent glaucoma in at-risk patients.
"It is critical to continue to evaluate and refine innovative, predictive
models in ophthalmic medicine in order to provide the best treatment possible
for patients," said Dr. Michael Kass. "We hope this tool will become as
universally adapted as predictive models used in other therapeutic areas, such
as the Framingham Study, which provided a basis for accurate cardiac risk
assessment."
"For some time we have known that if we could identify those patients most
likely to progress to glaucoma, earlier intervention with effective treatments
could help reduce the risk of vision impairment," said Dr. Robert N. Weinreb,
director of the Hamilton Glaucoma Center and Distinguished Professor of
Ophthalmology at the University of California, San Diego, USA. "This new
analysis provides a larger-scale validation of breakthrough findings of the
OHTS group and reinforces to clinicians how the tool can be useful in
assessing which patients are most at risk."
The OHTS prediction model was tested on patients in the EGPS placebo group
and the two study samples from the control (non-treated) arms were pooled to
increase precision and generalizability of a five-year predictive model for
developing POAG. The OHTS observation group contained 819 patients with a
median follow up of every six months for 6.6 years. The EGPS placebo group
contained 500 patients with a median follow up of every six months for 4.8
years.
"We know that awareness of these predictors, particularly elevated
intraocular pressure, and central corneal thickness, is critical in treating
and potentially preventing damage to the optic nerve caused by glaucoma
progression," said Professor Stefano Miglior, director of the Department of
Ophthalmology, Policlinico di Monza, University of Milan Bicocca, Italy, and
Chairman of EGPS. "The large-scale validation, which includes a European
patient population for the first time, reinforces the consensus about the
importance of informed dialogue between physicians and patients on how often
eye examinations are needed and when it might be appropriate to initiate
treatment."
The research was supported by grants from Pfizer Inc, (Nachrichten/Aktienkurs) the National Eye
Institute and the National Center for Minority Health and Health Disparities,
National Institutes of Health, the European Commission and Research to Prevent
Blindness and Merck Research Laboratories.
Pfizer's current product line includes the most prescribed treatment to
lower elevated eye pressure in patients with ocular hypertension (abnormally
high eye pressure) or open-angle glaucoma. In collaboration with (OSI)
Eyetech, the division also includes a treatment for neovascular age-related
macular degeneration.
SOURCE Pfizer Inc
-0- 11/15/2006
/CONTACT: Judy Brooks of Pfizer Inc, +1-212-573-7897/
/Photo: A free corporate logo to accompany this story is available
immediately via Wieck Photo Database to any media with telephoto receiver
or electronic darkroom, PC or Macintosh, that can accept overhead
transmissions. To retrieve a logo, please call 972-392-0888./
/Web site: http://www.pfizer.com /
(PFE)
Noch mal runter auf 23,5$ oder nicht?!
[URL]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1792173[/URL]
[URLChart öffnen]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1792173[/URL]
Denke schon das es nochmal kracht:
[URL]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1792181[/URL]
[URLChart öffnen]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1792181[/URL]
[URL]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1792173[/URL]
[URLChart öffnen]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1792173[/URL]
Denke schon das es nochmal kracht:
[URL]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1792181[/URL]
[URLChart öffnen]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1792181[/URL]
15.11.2006 14:31
Pfizer Animal Health Agrees to Acquire Embrex, Inc., the Leader in 'In Ovo' Poultry Vaccine-Delivery Technology
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 15 /PRNewswire-FirstCall/ -- Pfizer (Nachrichten/Aktienkurs) Animal Health, a division of Pfizer Inc has agreed to acquire Embrex, Inc. , an international agricultural biotechnology company known for its Inovoject(R) vaccine-delivery systems, the companies announced today.
Under the terms of the agreement, Pfizer will acquire through a merger 100 percent of the equity of Embrex for $17 per share in cash, making Embrex a wholly-owned subsidiary of Pfizer Inc. The transaction has an aggregate equity purchase price of approximately $155 million.
The acquisition is subject to approval by the shareholders of Embrex, other customary closing conditions, clearance under the Hart-Scott-Rodino Antitrust Improvements Act and certain foreign filings. The two companies expect to complete the acquisition in the first quarter of 2007.
In 2005, Embrex reported revenues of $52.5 million, up 8 percent over 2004. Sales outside the United States accounted for 37 percent of total revenues. Shares of Embrex common stock closed at $11.92 on Tuesday, November 14, 2006.
"This acquisition represents an excellent opportunity to leverage Embrex's innovative technologies and for Pfizer to reenter the poultry business," said Juan Ramon Alaix, president, Pfizer Animal Health. "Given the strength and breadth of our current non-poultry product lines and our industry leadership in research, we are confident that Embrex is a strong strategic fit for Pfizer's business model and our robust new-product pipeline."
"Biologicals are a rapidly growing segment of Pfizer Animal Health's overall sales," Mr. Alaix added. "We are excited by the chance to dedicate a portion of our research investment to discover and develop new vaccines that will address unmet needs of poultry producers and their birds."
"Embrex, founded in North Carolina in 1985, pioneered the development and use of in ovo injection technology, an approach that improved the consistency and reliability of vaccine delivery in the poultry industry," said Randall L. Marcuson, president and chief executive officer, Embrex, Inc. "As a key addition to Pfizer Animal Health, Embrex welcomes the growth opportunities afforded by Pfizer's financial and research resources."
With 2005 sales of $2.2 billion, Pfizer Animal Health is a global leader in discovering, developing and marketing medicines and vaccines for livestock, including beef and dairy cattle and swine, and companion animals. Since selling off its feed-additive business in 2000 to focus on more innovative products, Pfizer has not served the poultry market.
Embrex is best known for its Inovoject(R) system, now used to vaccinate more than 80 percent of the poultry raised in North America against Marek's disease. Embrex is also active in developing new poultry vaccines and vaccine-delivery technologies.
This release contains forward-looking statements about Embrex, its technologies and Pfizer's agreement to acquire Embrex. These statements involve substantial risks and uncertainties that could cause actual results to differ materially. Risks include without limitation the possibility that fewer than the required number of Embrex shareholders vote to approve the merger, the occurrence of events that would have a material adverse effect on Embrex as described in the merger agreement, delays in obtaining or failure to receive required regulatory approvals, including clearance under the Hart- Scott-Rodino Antitrust Improvements Act, the risk that the merger agreement could be terminated under circumstances that would require Embrex to pay a termination fee of $5 million and other uncertainties arising in connection with the proposed merger. Additional risks that could cause actual results to differ materially are discussed in Embrex's and Pfizer's Forms 10-K, 10-Q and other filings with the Securities and Exchange Commission.
Additional Information and Where to Find It
This communication may be deemed to be solicitation material in respect of the proposed acquisition of Embrex by Pfizer. Embrex will file a proxy statement and other documents regarding the proposed merger described in this press release with the U.S. Securities and Exchange Commission ("SEC"). SHAREHOLDERS OF EMBREX ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING EMBREX'S PROXY STATEMENT, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the proxy statement and other relevant documents free of charge at the SEC's web site, http://www.sec.gov/, and Embrex shareholders will receive information at an appropriate time on how to obtain the proxy statement and other transaction-related documents for free from Embrex. Such documents are not currently available.
Embrex and its directors, executive officers, certain members of management and employees may be deemed to be participants in the solicitation of proxies of Embrex shareholders to approve the proposed merger. Such individuals may have interests in the merger, including as a result of holding shares or options to purchase or shares of Embrex stock. Certain information regarding the participants and their interest in the solicitation is set forth in the proxy statement for Embrex's 2005 annual meeting of shareholders filed with the SEC on April 13, 2006.
Shareholders may obtain additional information regarding the interests of such participants by reading the proxy statement relating to the proposed transaction when it becomes available.
Photo: A free corporate logo to accompany this story is available
immediately via Wieck Photo Database to any media with telephoto receiver
or electronic darkroom, PC or Macintosh, that can accept overhead
transmissions. To retrieve a logo, please call 972-392-0888.
Pfizer Animal Health Agrees to Acquire Embrex, Inc., the Leader in 'In Ovo' Poultry Vaccine-Delivery Technology
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 15 /PRNewswire-FirstCall/ -- Pfizer (Nachrichten/Aktienkurs) Animal Health, a division of Pfizer Inc has agreed to acquire Embrex, Inc. , an international agricultural biotechnology company known for its Inovoject(R) vaccine-delivery systems, the companies announced today.
Under the terms of the agreement, Pfizer will acquire through a merger 100 percent of the equity of Embrex for $17 per share in cash, making Embrex a wholly-owned subsidiary of Pfizer Inc. The transaction has an aggregate equity purchase price of approximately $155 million.
The acquisition is subject to approval by the shareholders of Embrex, other customary closing conditions, clearance under the Hart-Scott-Rodino Antitrust Improvements Act and certain foreign filings. The two companies expect to complete the acquisition in the first quarter of 2007.
In 2005, Embrex reported revenues of $52.5 million, up 8 percent over 2004. Sales outside the United States accounted for 37 percent of total revenues. Shares of Embrex common stock closed at $11.92 on Tuesday, November 14, 2006.
"This acquisition represents an excellent opportunity to leverage Embrex's innovative technologies and for Pfizer to reenter the poultry business," said Juan Ramon Alaix, president, Pfizer Animal Health. "Given the strength and breadth of our current non-poultry product lines and our industry leadership in research, we are confident that Embrex is a strong strategic fit for Pfizer's business model and our robust new-product pipeline."
"Biologicals are a rapidly growing segment of Pfizer Animal Health's overall sales," Mr. Alaix added. "We are excited by the chance to dedicate a portion of our research investment to discover and develop new vaccines that will address unmet needs of poultry producers and their birds."
"Embrex, founded in North Carolina in 1985, pioneered the development and use of in ovo injection technology, an approach that improved the consistency and reliability of vaccine delivery in the poultry industry," said Randall L. Marcuson, president and chief executive officer, Embrex, Inc. "As a key addition to Pfizer Animal Health, Embrex welcomes the growth opportunities afforded by Pfizer's financial and research resources."
With 2005 sales of $2.2 billion, Pfizer Animal Health is a global leader in discovering, developing and marketing medicines and vaccines for livestock, including beef and dairy cattle and swine, and companion animals. Since selling off its feed-additive business in 2000 to focus on more innovative products, Pfizer has not served the poultry market.
Embrex is best known for its Inovoject(R) system, now used to vaccinate more than 80 percent of the poultry raised in North America against Marek's disease. Embrex is also active in developing new poultry vaccines and vaccine-delivery technologies.
This release contains forward-looking statements about Embrex, its technologies and Pfizer's agreement to acquire Embrex. These statements involve substantial risks and uncertainties that could cause actual results to differ materially. Risks include without limitation the possibility that fewer than the required number of Embrex shareholders vote to approve the merger, the occurrence of events that would have a material adverse effect on Embrex as described in the merger agreement, delays in obtaining or failure to receive required regulatory approvals, including clearance under the Hart- Scott-Rodino Antitrust Improvements Act, the risk that the merger agreement could be terminated under circumstances that would require Embrex to pay a termination fee of $5 million and other uncertainties arising in connection with the proposed merger. Additional risks that could cause actual results to differ materially are discussed in Embrex's and Pfizer's Forms 10-K, 10-Q and other filings with the Securities and Exchange Commission.
Additional Information and Where to Find It
This communication may be deemed to be solicitation material in respect of the proposed acquisition of Embrex by Pfizer. Embrex will file a proxy statement and other documents regarding the proposed merger described in this press release with the U.S. Securities and Exchange Commission ("SEC"). SHAREHOLDERS OF EMBREX ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING EMBREX'S PROXY STATEMENT, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the proxy statement and other relevant documents free of charge at the SEC's web site, http://www.sec.gov/, and Embrex shareholders will receive information at an appropriate time on how to obtain the proxy statement and other transaction-related documents for free from Embrex. Such documents are not currently available.
Embrex and its directors, executive officers, certain members of management and employees may be deemed to be participants in the solicitation of proxies of Embrex shareholders to approve the proposed merger. Such individuals may have interests in the merger, including as a result of holding shares or options to purchase or shares of Embrex stock. Certain information regarding the participants and their interest in the solicitation is set forth in the proxy statement for Embrex's 2005 annual meeting of shareholders filed with the SEC on April 13, 2006.
Shareholders may obtain additional information regarding the interests of such participants by reading the proxy statement relating to the proposed transaction when it becomes available.
Photo: A free corporate logo to accompany this story is available
immediately via Wieck Photo Database to any media with telephoto receiver
or electronic darkroom, PC or Macintosh, that can accept overhead
transmissions. To retrieve a logo, please call 972-392-0888.
Keine Panik,
ist doch wunderbar, immer einsammeln,
kuckt euch Merck&Co an,
Pfizer wird nachfolgen,
und die Dividendenrendite ist auch okay.
Gruß,
Snjezana (die fleissig einsammelt)
ist doch wunderbar, immer einsammeln,
kuckt euch Merck&Co an,
Pfizer wird nachfolgen,
und die Dividendenrendite ist auch okay.
Gruß,
Snjezana (die fleissig einsammelt)
pfizer macht wirklich keine freude. werde gewinne realisieren und abwarten.
Antwort auf Beitrag Nr.: 24.800.965 von heob am 23.10.06 15:59:43Hällt die 27€ Barriere oder nicht?
Mal grob analysiert, könnt fundamental doch ein Anstieg über die 30$ gerechtfertigt sein!
Oder tesetn wir nochmal den Aufwärtstrend?
[URL]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1758431[/URL]
[URLChart öffnen]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1758431[/URL]
Bitte nicht sonst kommt mein Stopp Loss für meine Knock outs dran
[URL]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1758433[/URL]
[URLChart öffnen]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1758433[/URL]
Mal grob analysiert, könnt fundamental doch ein Anstieg über die 30$ gerechtfertigt sein!
Oder tesetn wir nochmal den Aufwärtstrend?
[URL]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1758431[/URL]
[URLChart öffnen]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1758431[/URL]
Bitte nicht sonst kommt mein Stopp Loss für meine Knock outs dran
[URL]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1758433[/URL]
[URLChart öffnen]http://www.tradesignalonline.com/content.asp?p=wpa/tsb/default.asp&fcid=1758433[/URL]
Pfizer-Pharmawert total unterbewertet! 50% möglich!